Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Efficacy and Safety of Trans Sodium Crocetinate (TSC) Administered Onboard Emergency Vehicles for Treatment of Suspected Stroke: PHAST-TSC

Trial Profile

Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Efficacy and Safety of Trans Sodium Crocetinate (TSC) Administered Onboard Emergency Vehicles for Treatment of Suspected Stroke: PHAST-TSC

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Transcrocetinate sodium (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms PHAST-T; PHAST-TSC; PHAST-TSC
  • Sponsors Diffusion Pharmaceuticals
  • Most Recent Events

    • 14 Dec 2020 Status changed from suspended to discontinued due to lack of meaningful enrollment due to the COVID-19 pandemic.
    • 01 Sep 2020 Status changed from recruiting to suspended in response to logistical problems involving COVID-19 and on-ambulance treatment and other factors, for at least the duration of the pandemic while the company focuses its resources on developing TSC for use in the treatment of hospitalized COVID-19 patients.
    • 27 Apr 2020 According to a Diffusion Pharmaceuticals media release, enrollment in this trial is expected to be minimal until the COVID-19 pandemic abates.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top